129 related articles for article (PubMed ID: 20530698)
1. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Bäuerle T; Merz M; Komljenovic D; Zwick S; Semmler W
Clin Cancer Res; 2010 Jun; 16(12):3215-25. PubMed ID: 20530698
[TBL] [Abstract][Full Text] [Related]
2. Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases.
Merz M; Komljenovic D; Semmler W; Bäuerle T
Invest Radiol; 2012 Jul; 47(7):422-9. PubMed ID: 22659593
[TBL] [Abstract][Full Text] [Related]
3. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
Bäuerle T; Komljenovic D; Merz M; Berger MR; Goodman SL; Semmler W
Int J Cancer; 2011 May; 128(10):2453-62. PubMed ID: 20648558
[TBL] [Abstract][Full Text] [Related]
4. Cilengitide inhibits metastatic bone colonization in a nude rat model.
Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
[TBL] [Abstract][Full Text] [Related]
5. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted imaging and dynamic contrast-enhanced MRI of experimental breast cancer bone metastases--a correlation study with histology.
Merz M; Seyler L; Bretschi M; Semmler W; Bäuerle T
Eur J Radiol; 2015 Apr; 84(4):623-30. PubMed ID: 25641009
[TBL] [Abstract][Full Text] [Related]
7. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.
Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F
J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117
[TBL] [Abstract][Full Text] [Related]
8. Multi-modal imaging of angiogenesis in a nude rat model of breast cancer bone metastasis using magnetic resonance imaging, volumetric computed tomography and ultrasound.
Bäuerle T; Komljenovic D; Berger MR; Semmler W
J Vis Exp; 2012 Aug; (66):e4178. PubMed ID: 22929330
[TBL] [Abstract][Full Text] [Related]
9. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Bäuerle T; Hilbig H; Bartling S; Kiessling F; Kersten A; Schmitt-Gräff A; Kauczor HU; Delorme S; Berger MR
Neoplasia; 2008 May; 10(5):511-20. PubMed ID: 18472968
[TBL] [Abstract][Full Text] [Related]
12. Assessing treatment response of osteolytic lesions by manual volumetry, automatic segmentation, and RECIST in experimental bone metastases.
Bretschi M; Fränzle A; Merz M; Hillengass J; Semmler W; Bendl R; Bäuerle T
Acad Radiol; 2014 Sep; 21(9):1177-84. PubMed ID: 24998693
[TBL] [Abstract][Full Text] [Related]
13. Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats.
Peterschmitt J; Bäuerle T; Berger MR
Clin Exp Metastasis; 2007; 24(6):449-59. PubMed ID: 17636409
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
Schem C; Bauerschlag D; Bender S; Lorenzen AC; Loermann D; Hamann S; Rösel F; Kalthoff H; Glüer CC; Jonat W; Tiwari S
BMC Cancer; 2013 Jan; 13():32. PubMed ID: 23347638
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
16. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
Marzola P; Degrassi A; Calderan L; Farace P; Crescimanno C; Nicolato E; Giusti A; Pesenti E; Terron A; Sbarbati A; Abrams T; Murray L; Osculati F
Clin Cancer Res; 2004 Jan; 10(2):739-50. PubMed ID: 14760097
[TBL] [Abstract][Full Text] [Related]
17. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats.
Li GW; Xu Z; Chang SX; Zhou L; Wang XY; Nian H; Shi X
Endocrinology; 2014 Dec; 155(12):4731-8. PubMed ID: 25243855
[TBL] [Abstract][Full Text] [Related]
18. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
